SAGA hires two new scientists to strengthen its R&D Team

LUND, Sweden — /October 28, 2021/ — SAGA Diagnostics AB, (“SAGA”), a cancer liquid biopsy and genomic testing company focused on precision oncology and non-invasive ultrasensitive monitoring of cancer patients, today announces that it has hired two new scientists to significantly strengthen SAGA’s Research and Development Team: Nuria Seguí, PhD as Senior Product Development Scientist, and Lucia Oton, PhD as Molecular Diagnostics Scientist, dPCR.

 

 

Dr. Nuria Seguí is an expert in the development of new NGS products. She earned her PhD in hereditary cancer at the Catalan Institute of Oncology-Idibell, and had a three-year post-doctoral fellowship at the University of Cambridge in NGS-based cancer molecular diagnostics. Prior to joining SAGA’s R&D unit with a strong focus on NGS product development, she was a product development scientist at Aniling (Barcelona) working on genomic and epigenomic analyses. At SAGA she will now focus on the further development of the SAGAseq® and SAGAsign® solutions for eventual clinical implementation.

 

 

 

Dr. Lucia Oton has an extensive background in biomedical science and biotechnology research. She earned her PhD at the University of Ferrara, Italy, studying oncogenic viruses, in particular human papillomaviruses (HPV), and their involvement in head and neck cancers, as well as diagnostic and prognostic biomarker research using dPCR. She also had cancer research experiences at the University Hospital of Zurich, Switzerland, and the Hackensack University Medical Center, New Jersey, USA. Dr. Oton joins the dPCR group to work on the development and CE-marking of ultrasensitive SAGAsafe® assays.

 

 

We are delighted to welcome Nuria and Lucia to the SAGA team. With their expertise we will be able to accelerate the development of RUO and CE-marked SAGAsign®, SAGAseq®, and SAGAsafe® technologies, and expand SAGA’s medical device offerings significantly.
Lao Saal, COO, Head of R&D, and co-Founder of SAGA Diagnostics

 


 

Contact:

CEO Peter Collins  media@sagadiagnostics.com  Phone: +46 (0) 733 01 7242

Media:

Richard Hayhurst/Ola Björkman  richard@rhapr.eu  Phone: +44 (0) 7711 821527

 

About SAGA Diagnostics AB
SAGA Diagnostics is a personalized cancer genomics and disease monitoring company that offers molecular genetic testing of tissue biopsies and non-invasive “liquid biopsies” such as blood samples. SAGA helps pharmaceutical companies, scientists, and healthcare providers to detect actionable mutations, stratify patient groups, and monitor treatment response more accurately and to an industry-leading lower limit of detection of 0.001%. Analysis of circulating tumor DNA using its proprietary technologies gives SAGA unique ultrasensitivity, and provides the basis for optimal decision-making.

Follow SAGA on Twitter @SAGAdiagnostics and LinkedIn.